In Reply
Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2016-12, Vol.21 (12), p.e5-e6 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e6 |
|---|---|
| container_issue | 12 |
| container_start_page | e5 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 21 |
| creator | Brandi, Giovanni Deserti, Marzia Vasuri, Francesco Farioli, Andrea Degiovanni, Alessio Palloni, Andrea Frega, Giorgio Barbera, Maria A. de Lorenzo, Stefania Garajova, Ingrid Di Marco, Mariacristina Pinna, Antonio D. Cescon, Matteo Cucchetti, Alessandro Ercolani, Giorgio D’Errico-Grigioni, Antonietta Pantaleo, Maria A. Biasco, Guido Tavolari, Simona |
| description | Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study. |
| doi_str_mv | 10.1634/theoncologist.2016-0286 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1634_theoncologist_2016_0286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1634_theoncologist_2016_0286</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1634_theoncologist_2016_02863</originalsourceid><addsrcrecordid>eNpjYJA3NNAzNDM20S_JSM3PS87PyU_PLC7RMzIwNNM1MLIwY2LgNDQ1sdQ1sTSIYAGyDSyMdc0NTS05GLiKi7MMDIBMYyNOBg7PPIWg1IKcSh4G1rTEnOJUXijNzWDu5hri7KGbXJRfXFyUmhZfUJSZm1hUGW9oEA-yOB7F4niQxfEgi43J1wkAcYA85w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>In Reply</title><source>Oxford Journals Open Access Collection</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Brandi, Giovanni ; Deserti, Marzia ; Vasuri, Francesco ; Farioli, Andrea ; Degiovanni, Alessio ; Palloni, Andrea ; Frega, Giorgio ; Barbera, Maria A. ; de Lorenzo, Stefania ; Garajova, Ingrid ; Di Marco, Mariacristina ; Pinna, Antonio D. ; Cescon, Matteo ; Cucchetti, Alessandro ; Ercolani, Giorgio ; D’Errico-Grigioni, Antonietta ; Pantaleo, Maria A. ; Biasco, Guido ; Tavolari, Simona</creator><creatorcontrib>Brandi, Giovanni ; Deserti, Marzia ; Vasuri, Francesco ; Farioli, Andrea ; Degiovanni, Alessio ; Palloni, Andrea ; Frega, Giorgio ; Barbera, Maria A. ; de Lorenzo, Stefania ; Garajova, Ingrid ; Di Marco, Mariacristina ; Pinna, Antonio D. ; Cescon, Matteo ; Cucchetti, Alessandro ; Ercolani, Giorgio ; D’Errico-Grigioni, Antonietta ; Pantaleo, Maria A. ; Biasco, Guido ; Tavolari, Simona</creatorcontrib><description>Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1634/theoncologist.2016-0286</identifier><language>eng</language><ispartof>The oncologist (Dayton, Ohio), 2016-12, Vol.21 (12), p.e5-e6</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-crossref_primary_10_1634_theoncologist_2016_02863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Brandi, Giovanni</creatorcontrib><creatorcontrib>Deserti, Marzia</creatorcontrib><creatorcontrib>Vasuri, Francesco</creatorcontrib><creatorcontrib>Farioli, Andrea</creatorcontrib><creatorcontrib>Degiovanni, Alessio</creatorcontrib><creatorcontrib>Palloni, Andrea</creatorcontrib><creatorcontrib>Frega, Giorgio</creatorcontrib><creatorcontrib>Barbera, Maria A.</creatorcontrib><creatorcontrib>de Lorenzo, Stefania</creatorcontrib><creatorcontrib>Garajova, Ingrid</creatorcontrib><creatorcontrib>Di Marco, Mariacristina</creatorcontrib><creatorcontrib>Pinna, Antonio D.</creatorcontrib><creatorcontrib>Cescon, Matteo</creatorcontrib><creatorcontrib>Cucchetti, Alessandro</creatorcontrib><creatorcontrib>Ercolani, Giorgio</creatorcontrib><creatorcontrib>D’Errico-Grigioni, Antonietta</creatorcontrib><creatorcontrib>Pantaleo, Maria A.</creatorcontrib><creatorcontrib>Biasco, Guido</creatorcontrib><creatorcontrib>Tavolari, Simona</creatorcontrib><title>In Reply</title><title>The oncologist (Dayton, Ohio)</title><description>Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.</description><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpjYJA3NNAzNDM20S_JSM3PS87PyU_PLC7RMzIwNNM1MLIwY2LgNDQ1sdQ1sTSIYAGyDSyMdc0NTS05GLiKi7MMDIBMYyNOBg7PPIWg1IKcSh4G1rTEnOJUXijNzWDu5hri7KGbXJRfXFyUmhZfUJSZm1hUGW9oEA-yOB7F4niQxfEgi43J1wkAcYA85w</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Brandi, Giovanni</creator><creator>Deserti, Marzia</creator><creator>Vasuri, Francesco</creator><creator>Farioli, Andrea</creator><creator>Degiovanni, Alessio</creator><creator>Palloni, Andrea</creator><creator>Frega, Giorgio</creator><creator>Barbera, Maria A.</creator><creator>de Lorenzo, Stefania</creator><creator>Garajova, Ingrid</creator><creator>Di Marco, Mariacristina</creator><creator>Pinna, Antonio D.</creator><creator>Cescon, Matteo</creator><creator>Cucchetti, Alessandro</creator><creator>Ercolani, Giorgio</creator><creator>D’Errico-Grigioni, Antonietta</creator><creator>Pantaleo, Maria A.</creator><creator>Biasco, Guido</creator><creator>Tavolari, Simona</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161201</creationdate><title>In Reply</title><author>Brandi, Giovanni ; Deserti, Marzia ; Vasuri, Francesco ; Farioli, Andrea ; Degiovanni, Alessio ; Palloni, Andrea ; Frega, Giorgio ; Barbera, Maria A. ; de Lorenzo, Stefania ; Garajova, Ingrid ; Di Marco, Mariacristina ; Pinna, Antonio D. ; Cescon, Matteo ; Cucchetti, Alessandro ; Ercolani, Giorgio ; D’Errico-Grigioni, Antonietta ; Pantaleo, Maria A. ; Biasco, Guido ; Tavolari, Simona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1634_theoncologist_2016_02863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brandi, Giovanni</creatorcontrib><creatorcontrib>Deserti, Marzia</creatorcontrib><creatorcontrib>Vasuri, Francesco</creatorcontrib><creatorcontrib>Farioli, Andrea</creatorcontrib><creatorcontrib>Degiovanni, Alessio</creatorcontrib><creatorcontrib>Palloni, Andrea</creatorcontrib><creatorcontrib>Frega, Giorgio</creatorcontrib><creatorcontrib>Barbera, Maria A.</creatorcontrib><creatorcontrib>de Lorenzo, Stefania</creatorcontrib><creatorcontrib>Garajova, Ingrid</creatorcontrib><creatorcontrib>Di Marco, Mariacristina</creatorcontrib><creatorcontrib>Pinna, Antonio D.</creatorcontrib><creatorcontrib>Cescon, Matteo</creatorcontrib><creatorcontrib>Cucchetti, Alessandro</creatorcontrib><creatorcontrib>Ercolani, Giorgio</creatorcontrib><creatorcontrib>D’Errico-Grigioni, Antonietta</creatorcontrib><creatorcontrib>Pantaleo, Maria A.</creatorcontrib><creatorcontrib>Biasco, Guido</creatorcontrib><creatorcontrib>Tavolari, Simona</creatorcontrib><collection>CrossRef</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brandi, Giovanni</au><au>Deserti, Marzia</au><au>Vasuri, Francesco</au><au>Farioli, Andrea</au><au>Degiovanni, Alessio</au><au>Palloni, Andrea</au><au>Frega, Giorgio</au><au>Barbera, Maria A.</au><au>de Lorenzo, Stefania</au><au>Garajova, Ingrid</au><au>Di Marco, Mariacristina</au><au>Pinna, Antonio D.</au><au>Cescon, Matteo</au><au>Cucchetti, Alessandro</au><au>Ercolani, Giorgio</au><au>D’Errico-Grigioni, Antonietta</au><au>Pantaleo, Maria A.</au><au>Biasco, Guido</au><au>Tavolari, Simona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Reply</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>21</volume><issue>12</issue><spage>e5</spage><epage>e6</epage><pages>e5-e6</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Brandi et al. clarify data about the localization of human equilibrative nucleoside transporter 1 in cancer patients receiving gemcitabine-based chemotherapy. They discuss methodology, differences between antibodies, and recommendations for further study.</abstract><doi>10.1634/theoncologist.2016-0286</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2016-12, Vol.21 (12), p.e5-e6 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_crossref_primary_10_1634_theoncologist_2016_0286 |
| source | Oxford Journals Open Access Collection; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| title | In Reply |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A57%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Reply&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Brandi,%20Giovanni&rft.date=2016-12-01&rft.volume=21&rft.issue=12&rft.spage=e5&rft.epage=e6&rft.pages=e5-e6&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1634/theoncologist.2016-0286&rft_dat=%3Ccrossref%3E10_1634_theoncologist_2016_0286%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |